Navigation Links
BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
Date:3/23/2009

NEW HAVEN, Conn. and TORONTO, March 23 /PRNewswire/ -- BioRelix, pioneers in the discovery and development of Riboswitch based therapeutic agents, and Dalton Medicinal Chemistry have jointly announced an expansion and renewal of their exclusive worldwide collaboration and agreement to discover and develop new therapeutics.

Dalton Medicinal Chemistry will apply their proprietary insights to the design and synthesis of new classes of compounds against selected Riboswitch targets. BioRelix will advance these compounds with their cutting edge array of biological assays and thorough knowledge of Riboswitch drug discovery and development.

Brian Dixon, BioRelix CEO commented, "We are pleased to have the opportunity to expand and renew our productive relationship with the creative team at Dalton Medicinal Chemistry. We are confident their expertise, insights and commitment to high quality medicinal chemistry, coupled with our propriety and leading position on Riboswitches, will continue to deliver value in important new medicines."

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: "We are delighted to work further with BioRelix in the discovery and development of much needed new anti-infective agents. The team at BioRelix has clearly established a remarkably innovative and fundamentally groundbreaking approach to anti-infectives and we are pleased to be with them at the forefront of this medicinal chemistry and drug discovery."

About BioRelix:

BioRelix, Inc. is a drug discovery and development company focused on identifying new anti-infective drug treatments. BioRelix is building a portfolio of anti-infective product candidates based on novel patented RNA targets, termed Riboswitches, which were identified by the laboratory of BioRelix co-founder, Ronald Breaker, Ph.D., Howard Hughes Investigator and Henry Ford II Professor at Yale University. BioRelix investors include CHL Medical Partners, Novartis Venture Fund, Aisling Capital, New Leaf Venture Partners, Elm Street Ventures and Alexandria Real Estate Equities.

About Dalton Medicinal Chemistry:

Dalton Medicinal Chemistry is a drug discovery company focused on the design, synthesis and advancement of new chemical entities in partnership with Biotech and Pharma.


'/>"/>
SOURCE Dalton Medicinal Chemistry
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals
2. BioRelix and Dalton Medicinal Chemistry Sign Research Agreement to Capitalize on RiboSwitch Technology
3. Dalton Pharma Services Licenses Thermo Fisher Scientific Technology to Produce Polynucleotides for Drug Development
4. BIKAM and Dalton Medicinal Chemistry Sign Collaborative Research Agreement
5. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
6. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
7. Acesys and Provid Announce Alliance for Medicinal Chemistry Services
8. Telik Announces Publication of Diabetes Research in Bioorganic & Medicinal Chemistry Letters
9. MS Drug Development Agreement Based on WEHIs Medicinal Chemistry
10. Neptune Technologies expands into medicinal markets in Asia Pacific
11. New 300mg Loading Dose Tablet for Plavix(R) Receives Positive Opinion From the European Committee for Medicinal Products (CHMP)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Robots will storm the Prudential Center in ... 2016. The event, which is held on the United Nations International Day of Persons ... back into the workplace. Suitable Technologies is partnering with NTI to showcase how technology ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... moving magnet Voice Coil Actuator with a flexure design that ensures high alignment ... with cost-effective pricing and is ideally suited where extreme precision is required, such ...
(Date:11/30/2016)... 30, 2016 Biotest Pharmaceuticals Corporation (BPC), a ... announce the addition of its newest plasma collection center ... . The 15,200 square foot state-of-the-art facility officially ... and brings the total number of BPC,s plasma collection ... , BPC,s Chief Executive Officer said "We are pleased ...
(Date:11/30/2016)... DIEGO and BEIJING , ... a leading commercial provider of genomic services and solutions ... announced today that it has completed a USD $75 ... Merchants Bank Co., Ltd.,s CMB International Capital Management ( ... Innovation Investment Management Co., Ltd. ("SDIC Innovation") and Shanghai ...
Breaking Biology Technology:
(Date:11/22/2016)... November 22, 2016 According to the new market ... Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact ... MarketsandMarkets, the market is expected to grow from USD 10.74 Billion in ... 16.79% between 2016 and 2022. Continue Reading ... ...
(Date:11/21/2016)... , Nov. 21, 2016   Neurotechnology ... object recognition technologies, today announced that the MegaMatcher ... cards was submitted for the NIST Minutiae ... passed all the mandatory steps of the evaluation ... is a continuing test of fingerprint templates used ...
(Date:11/17/2016)... -- Global Market Watch: Primarily supported by ownership ... and Academics) market is to witness a value of US$37.1 ... highest Compounded Annual Growth Rate (CAGR) of 10.75% is foreseen ... period 2014-2020. North America is not ... Europe at 9.56% respectively. Report Focus: ...
Breaking Biology News(10 mins):